The Non-Prescription Drugs industry on FinBizNet covers 9 listed companies, with broker-view summaries, sub-industry segmentation, latest quarterly results and peer comparisons for each constituent.
| Listed companies | 9 |
|---|---|
| Combined market cap | ₹71,467 Cr |
| Median P/E (profitable companies) | 24.1 |
| Median return on equity | 12.4% |
| Companies with latest quarterly results | 5 of 9 |
| Company | Market Cap | P/E | ROE | Quarterly Revenue | Quarterly Net Profit | Quarter |
|---|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹42,832 Cr | 41.3 | 48.9% | ₹1,184 Cr | ₹336 Cr | Q2 FY27 |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹15,784 Cr | 23.4 | 12.4% | ₹2,603 Cr | ₹334 Cr | Q2 FY27 |
| Bliss Gvs Pharma Ltd. | ₹6,557 Cr | 51.4 | 11.6% | ₹313 Cr | ₹53 Cr | Q2 FY27 |
| Zota Health Care Ltd | ₹4,215 Cr | — | -16.1% | ₹199 Cr | ₹-26 Cr | Q2 FY27 |
| Amrutanjan Health Care Ltd. | ₹1,437 Cr | 24.8 | 16.6% | ₹135 Cr | ₹17 Cr | Q2 FY27 |
| Jenburkt Pharmaceuticals Ltd. | ₹380 Cr | 10.9 | 18.8% | — | — | — |
| Sat Kartar Life Limited | ₹200 Cr | 11.7 | 25.3% | — | — | — |
| Vista Pharmaceuticals Ltd. | ₹39 Cr | — | -10.8% | — | — | — |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | — | -5.5% | — | — | — |
Market data from the FinBizNet stock universe; quarterly figures in ₹ crore, parsed from each company's exchange filing (XBRL).
FinBizNet tracks 9 listed companies in the Non-Prescription Drugs industry, including Glaxosmithkline Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited (Aplltd), Bliss Gvs Pharma Ltd., Zota Health Care Ltd, Amrutanjan Health Care Ltd., Jenburkt Pharmaceuticals Ltd., Sat Kartar Life Limited, Vista Pharmaceuticals Ltd., among others.
By market capitalisation, the largest Non-Prescription Drugs companies are Glaxosmithkline Pharmaceuticals Ltd. (₹42,832 Cr), Alembic Pharmaceuticals Limited (Aplltd) (₹15,784 Cr), Bliss Gvs Pharma Ltd. (₹6,557 Cr), Zota Health Care Ltd (₹4,215 Cr), Amrutanjan Health Care Ltd. (₹1,437 Cr).
The 9 Non-Prescription Drugs companies tracked on FinBizNet have a combined market capitalisation of about ₹71,467 Cr.
The median price-to-earnings ratio across 6 profitable Non-Prescription Drugs companies is 24.1, and the median return on equity across the industry is 12.4%. Medians are shown for context only.
FinBizNet aggregates broker research, sub-industry breakdowns, quarterly results and peer-stock comparisons across the Non-Prescription Drugs industry.